Interactive modules by Olga Goodman, MD.Copyright protected · Read termsClose terms

All RheumaView™ interactive modules, quizzes and educational cases are original works developed by Olga Goodman, MD.

Without the author’s prior written permission, you may not copy or republish these modules or their components; extract, reuse or modify their original software code (“engines”); or use that code to build your own modules, quizzes or other products.

You may not claim these works as your own or remove or replace the author’s name or copyright notices. When quoting material, credit Olga Goodman, MD, identify the source and include a direct link to the original.

Free or public access is provided for learning and does not grant permission to copy, adapt or redistribute the materials. Unauthorized use of protected material may constitute copyright infringement. Exceptions and limitations provided by applicable law remain unaffected.

Sharing direct links to the modules is welcome.

© 2026 Olga Goodman, MD. All rights reserved.

Skip to article
Contents · Peripheral SpA
Chapter 4 · Diagnosis and phenotyping

Phenotyping Across Peripheral and Extra-musculoskeletal Domains

Build a reproducible domain record that distinguishes active inflammation, prior disease and functional impact before choosing treatment.

Open accessEvidence reviewed:
On this page

Describe what is active today

A disease label is a poor substitute for a phenotype. The same label may describe active oligoarthritis, enthesis-predominant symptoms, dactylitis, or controlled joint disease with persistent mechanical disability. Treatment decisions require a current domain record, while diagnostic reasoning also needs the cumulative history. Keep those two records connected but distinct.

Begin with an open account of what limits the patient, followed by a structured examination. Record the site, time course and objective support for each major symptom. “Peripheral disease active” is less useful than “two swollen ankles, plantar insertion pain with uncertain inflammatory contribution, no current dactylitis.” The second description makes both action and uncertainty visible.

Peripheral arthritis: count and characterize

Identify synovial swelling separately from tenderness, bony enlargement, edema and periarticular pathology. Record distribution, symmetry, joint size, range of motion and the functional consequences. A swollen knee that prevents walking can be more consequential than several minimally symptomatic small joints. Limited motion may reflect active synovitis, longstanding damage or another process.

Use a named joint-count system consistently. A 66-swollen/68-tender examination and a 44-joint examination cover different sets; they cannot be compared as if their raw numbers were interchangeable. A short 28-joint count is particularly liable to miss feet and other relevant peripheral sites. Clinical examination remains central; ultrasound can clarify uncertain synovitis when the result will change a decision. [1]

When findings are episodic, seek contemporaneous prior records and arrange reassessment during a meaningful flare where feasible. A patient’s photograph can help establish the chronology but does not reliably distinguish joint swelling from all surrounding causes. Avoid dismissing a credible history because the examination happens to be quiet, while also avoiding retrospective certainty that the available evidence cannot support.

Entheses: tenderness needs interpretation

Ask the patient to localize pain before palpation. Distinguish insertional pain from tendon-body pain, adjacent bursitis and referred pain. Examine both symptomatic sites and a consistent comparison set. Record recent loading, trauma, occupational demands, footwear, body habitus and widespread tenderness when relevant. These factors can coexist with inflammatory disease.

A clinical enthesitis index provides a reproducible count of tender sites, not histological proof of inflammation. The Leeds Enthesitis Index was developed in PsA and uses a small defined set of locations. [2] Its efficiency is useful, but a low score cannot describe every symptomatic enthesis. Add a site-specific note when the patient’s main problem falls outside the chosen index.

Ultrasound is most helpful when there is a genuine diagnostic or activity question. A DEUS analysis illustrates discordance between clinical tenderness and ultrasound-defined activity in axSpA/PsA. [3] That discordance should lead to interpretation of the particular tissue, technique and competing pain mechanisms, rather than assuming one measurement automatically invalidates the other.

Dactylitis: document the entire digit

Record the affected digit, current tenderness, duration, degree of diffuse swelling and functional effect. Distinguish current dactylitis from a credible past episode and from permanent enlargement. Assess adjacent skin, wounds, nail disease and focal tendon findings. A rapidly painful swollen digit after a puncture or with infection features requires a different urgency than a familiar inflammatory pattern.

For longitudinal comparison, count affected digits and retain a consistent approach to tenderness or circumference if used. Do not reduce a whole-digit lesion to the number of tender interphalangeal joints. Conversely, do not count every swollen finger as dactylitis when swelling is confined to one joint.

Skin, nails, bowel and eyes

Ask about current and previous psoriasis, then inspect accessible relevant sites with the patient’s consent. Scalp, retroauricular, umbilical and intergluteal disease may be missed by a routine exposed-skin examination. Nail pitting, onycholysis and dystrophy require clinical interpretation; uncertain lesions may warrant dermatology input. Record who established the diagnosis and whether current treatment may be suppressing visible lesions.

For bowel disease, distinguish established IBD from nonspecific symptoms. Persistent diarrhea, rectal bleeding, weight loss, nocturnal symptoms or iron deficiency may justify targeted gastrointestinal evaluation. Medication effects and other causes remain possible. The point is to identify a management-changing context, not to declare IBD from a symptom checklist.

For ocular history, distinguish documented anterior uveitis from an unspecified “red eye.” Recover ophthalmology records when feasible. A currently painful, photophobic red eye or reduced vision warrants urgent ophthalmic assessment. The phenotype should include recurrence and current activity because a remote resolved episode and frequently recurrent disease pose different treatment questions.

Axial disease is a separate assessment

Ask about onset, duration and character of back or buttock symptoms, stiffness, night pain and response to movement. These features influence suspicion but are not individually diagnostic. Evaluate mechanical and neurologic alternatives. Order axial imaging to answer a clinical question, with appropriate interpretation of inflammatory and structural lesions; do not order it merely to fill every possible classification box.

When axial disease is established, record whether it is currently driving treatment. “Peripheral SpA with back pain” and “active axSpA with peripheral arthritis” may require different evidence pathways even if both domains are present. Neither label erases the other domain.

A compact phenotype record

DomainCurrent activityHistory and impact
ArthritisNamed swollen/tender count; sites and examination certaintyPrior documented episodes, damage, walking and hand function
EnthesisSpecified index plus symptomatic sites; inflammation confidenceLoad, injury, prior imaging and occupational effect
DactylitisDigit count, tenderness and diffuse swellingPrior episodes and residual enlargement
AxialCurrent symptoms and objective assessment where indicatedChronology, prior imaging and previous diagnosis
Extra-musculoskeletalSkin/nail, bowel and eye activityConfirmed diagnoses, recurrence and other specialists’ plans
Patient impactPain, fatigue, participation and a concrete priorityChange from baseline and noninflammatory contributors

Translate phenotype into a decision

The domain-based approach in PsA guidance is a useful organizational comparison, while the treatment recommendations themselves remain PsA-specific. [4] For non-psoriatic pSpA, describe where treatment evidence is direct and where it is borrowed. First settle which inflammatory domain needs treatment; then consider associated organ disease, safety, previous exposure and patient priorities.

End the visit with a measurable target: less swelling, restored walking tolerance, recovery of hand function, or clarification of uncertain enthesis symptoms. At the next visit, compare the same domains. A changing global score should trigger inspection of its components rather than an assumption that all tissues improved or worsened together.

Evidence in context

Source status checked October 6, 2026. Population applicability and publication maturity are separate judgments.

Scrollable evidence table

SourcePopulation and phenotypeDesign and statusApplicabilityClinical implicationImportant limitationLast checked
EULAR early arthritis [1]Early inflammatory arthritisGuideline; peer-reviewedGeneral diagnostic approachClinical examination guides further testingNot a pSpA-specific treatment guideline2026-10-06
LEI development [2]PsAInstrument development; peer-reviewedPsA-derived assessmentStandardize specified enthesis sitesLimited anatomical coverage; tenderness is nonspecific2026-10-06
DEUS examination comparison [3]AxSpA and PsACross-sectional; peer-reviewedMixed SpA phenotypesClinical and ultrasound findings may disagreeNo universal treatment threshold from discordance2026-10-06
GRAPPA [4]PsA domains and related conditionsGuideline; peer-reviewedPsA-derived frameworkAssess all active domains and impactDo not relabel drug recommendations as direct non-psoriatic pSpA evidence2026-10-06

Sources

  1. Combe et al. EULAR recommendations for early arthritis: 2016 update
  2. Healy and Helliwell. Development of the Leeds Enthesitis Index (2008)
  3. Di Matteo et al. Ultrasound and physical examination in DEUS (2025)
  4. Coates et al. GRAPPA 2021 recommendations, published 2022

Share this page

FacebookLinkedInXWhatsAppTelegram

Topics: Peripheral SpASpondyloarthritis